EpiCypher Announces Sam Tetlow as Chief Executive Officer
Complete the form below to unlock access to ALL audio articles.
EpiCypher has announced that Sam Tetlow has been named Chief Executive Officer and a member of the Board of Directors. Both roles were previously not filled. EpiCypher will officially move the Company to North Carolina to undertake R&D and lab operations in Chapel Hill, NC. The Company has also announced that it has been accepted as part of the Blackstone Entrepreneurs Network.
“We are thrilled Sam has joined our team! We look forward to him leading the organization as we develop our differentiated portfolio of epigenetic products and help researchers achieve unprecedented results by using our products,” said Scientific Founders Mark Bedford Ph.D., Or Gozani, M.D. Ph.D., and Brian Strahl, Ph.D., in a joint statement. “Sam has already had an impact on customer adoption of our products and in realizing our strategic goals for 2014 and beyond. EpiCypher’s vision is to lead the epigenetics field to improve human health and Sam joining is an important step in realizing that vision.”
Sam joins Dr. Jim Bone, President and COO and Dr. Zu-Wen Sun, Chief Scientific Officer on the management team. Sam has a strong track record as a catalyst for growth of early-and-mid stage services, drug development, and medical technology companies in both management and investor roles. His experience includes leading organic growth, partnership development, strategic planning and company leadership.
Most recently Sam was CBO with ILS, where he led organic growth in the commercial sectors and launched ILS Genomics, following the purchase of Beckman Coulter Genomics. Sam was the General Manager of ILS Genomics, leading the Company from launch through its first full year of operations.
Prior to that, Sam was a lead director with Immunologix, a Medical University of South Carolina spinout that was launched, built and sold for a 10x return for investors within a 24-month period.
Prior to that, Sam was a full time Partner with Research Triangle Ventures, where he led the full cycle of life science investing which included serving as Executive Chairman of Gentris Corporation as well as managing the firm’s investment in Tranzyme Pharma, among others.
Sam has a Bachelor’s of Science from Worcester Polytechnic Institute (honors) and a MBA from UNC Kenan-Flagler Business School (honors).
